Published in Gene Therapy Weekly, October 18th, 2001
There seem to be too many barriers to effective intravenous gene therapy administration, according to S.K. Yoon, a researcher at Harvard Medical School in Boston Massachusetts. Yoon, collaborating in a multicenter study, hoped to gain a better understanding of the nature of gene therapy delivery in hepatocellular carcinoma (HCC). Gene therapy could potentially benefit thousands of people who develop primary liver cancers because of hepatitis viruses,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.